# Pharmacogenetics of Ace Inhibitor-Associated Angioedema

> **NCT01413542** · NA · COMPLETED · sponsor: **Vanderbilt University** · enrollment: 44 (actual)

## Conditions studied

- Hypertension
- Diabetes Type 2

## Interventions

- **DRUG:** Sitagliptin (DPP4 inhibitor)
- **DRUG:** Substance P,
- **DRUG:** bradykinin
- **DRUG:** enalaprilat (ACE inhibitor)
- **DRUG:** Glucagon-like peptide 1
- **DRUG:** brain natriuretic peptide

## Key facts

- **NCT ID:** NCT01413542
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-07
- **Final completion:** 2014-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2015-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01413542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01413542, "Pharmacogenetics of Ace Inhibitor-Associated Angioedema". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01413542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*